Galectin Therapeutics (NASDAQ:GALT) CFO Sells $100,354.80 in Stock

by · The Cerbat Gem

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) CFO Jack Callicutt sold 25,732 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $3.90, for a total transaction of $100,354.80. Following the completion of the sale, the chief financial officer owned 27,968 shares in the company, valued at approximately $109,075.20. The trade was a 47.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Galectin Therapeutics Stock Down 9.6%

Shares of Galectin Therapeutics stock opened at $3.20 on Friday. Galectin Therapeutics Inc. has a twelve month low of $1.07 and a twelve month high of $7.13. The business has a 50-day moving average price of $5.24 and a 200-day moving average price of $4.38. The firm has a market cap of $206.30 million, a price-to-earnings ratio of -5.42 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Galectin Therapeutics has an average rating of “Hold” and a consensus price target of $11.00.

Get Our Latest Report on Galectin Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GALT. Nuveen LLC bought a new position in Galectin Therapeutics during the first quarter valued at $34,000. Atwood & Palmer Inc. purchased a new position in shares of Galectin Therapeutics during the 3rd quarter worth about $42,000. Archer Investment Corp purchased a new position in shares of Galectin Therapeutics during the 3rd quarter worth about $47,000. Bank of America Corp DE grew its holdings in Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after purchasing an additional 19,316 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in Galectin Therapeutics in the 3rd quarter worth about $63,000. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

Read More